Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) Stock Ticker

NASDAQ: KNSA · Healthcare · Medical - Pharmaceuticals
$75.08-0.35%
USD · as of 2026-09-28 · market cap $5.7B
Open KNSA in TickrDownload for iPhone

KNSA right now

Options expect by Oct 6±5.7%
Options expect by Oct 29±11.9%
Priced in for Oct 27 earnings±11.5%
IV rank (30-day)16% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full KNSA picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on KNSA
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.

KNSA stock facts

Ticker symbolKNSA
ExchangeNASDAQ
SectorHealthcare
IndustryMedical - Pharmaceuticals
Market cap$5.7B
CEOSanj K. Patel
Employees366
HeadquartersLondon, GL, GB
IPO date2018-05-24
Websitewww.kiniksa.com

What you can see for KNSA on Tickr

Live KNSA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the KNSA report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Kiniksa Pharmaceuticals International, plc?

The ticker symbol for Kiniksa Pharmaceuticals International, plc is KNSA, listed on the NASDAQ.

What is KNSA?

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops…

HomeExploreMarketLists
All pages